Business Practice

Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma?

Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.

To shareholders – according to an analysis of financial reports from healthcare companies.

Within two years, pharma companies may be able to rely on technology to automatically create and cross-check entire regulatory submissions.

Why you shouldn’t neglect the importance of blending people, culture, and strategy to foster success in a business.

Here’s a roundup of ten of the most eye-catching deals so far in 2025.

The Trump administration’s move to pause federal funding while projects are vetted causes concern and lawsuits

Watch our video interview covering Claus Zieler’s career and passion for improving investment in Europe.

Welcome back to our interview series with Jon Thomas, President and CEO of the California Institute for Regenerative Medicine: CIRM.

Sitting Down With… Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult.